Home / Business and Economy / Alembic Pharma Gains USFDA Green Light for Glaucoma Treatment
Alembic Pharma Gains USFDA Green Light for Glaucoma Treatment
18 Dec, 2025
Summary
- Alembic Pharmaceuticals received USFDA final approval for Travoprost Ophthalmic Solution.
- This treatment is designed to reduce elevated intraocular pressure in glaucoma patients.
- The approved drug is therapeutically equivalent to Sandoz's Travatan Z Ophthalmic Solution.
Alembic Pharmaceuticals has announced a significant achievement with the US Food & Drug Administration granting final approval for its Travoprost Ophthalmic Solution USP, 0.004%. This newly approved generic medication is indicated for the crucial task of reducing elevated intraocular pressure in individuals diagnosed with open-angle glaucoma or ocular hypertension.
The approved solution is recognized as therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution, 0.004%, previously marketed by Sandoz Inc. This therapeutic equivalence assures patients and healthcare providers of its comparable efficacy and safety profile. Alembic Pharmaceuticals continues to expand its regulatory success with this latest approval.
This milestone further strengthens Alembic's position in the pharmaceutical market, contributing to its cumulative total of 232 ANDA approvals from the USFDA. The estimated market for this specific ophthalmic solution is substantial, reflecting the ongoing need for effective glaucoma treatments.
